Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?

Rao Y, Zheng F.

Int J Clin Pharm. 2013 Aug;35(4):529-31. doi: 10.1007/s11096-013-9778-8. Epub 2013 Apr 27.

PMID:
23625279
2.

[Thrombopenia during 5-ASA treatment (mesalazine and olsalazine)].

Benoit R, Grobost O, Bichoffe A, Dol L.

Gastroenterol Clin Biol. 1999 Mar;23(3):410-1. French. No abstract available.

3.

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.

Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schütz E, Otto P, Lorenz-Mayer H, Ewe K, Judmaier G.

Aliment Pharmacol Ther. 1998 Aug;12(8):707-15.

5.

Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories.

Casellas F, Vallano A, Malagelada JR.

J Clin Gastroenterol. 1996 Mar;22(2):160-1. No abstract available.

PMID:
8742664
6.

Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.

Singer MV, Schmausser H, Schönfeld G.

Hepatogastroenterology. 2006 May-Jun;53(69):317-21.

PMID:
16795963
7.

5-aminosalicylates in inflammatory bowel disease--the more the merrier?

Forbes A.

Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1017-9. No abstract available.

PMID:
8680898
8.

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.

Karamanolis DG, Papatheodoridis GV, Xourgias V.

Eur J Gastroenterol Hepatol. 1996 Nov;8(11):1083-8.

PMID:
8944370
9.

Hypersensitivity to 5-ASA suppositories.

Borum ML, Ginsberg A.

Dig Dis Sci. 1997 May;42(5):1076-8. Review. No abstract available.

PMID:
9149065
10.

A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.

Nikfar S, Rahimi R, Rezaie A, Abdollahi M.

Dig Dis Sci. 2009 Jun;54(6):1157-70. doi: 10.1007/s10620-008-0481-x. Epub 2008 Sep 4. Review.

PMID:
18770034
11.
12.

Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.

Gionchetti P, Campieri M, Venturi A, Rizzello F, Ferretti M, Brignola C, Miglioli M.

Aliment Pharmacol Ther. 1996 Aug;10(4):601-5.

PMID:
8853765
13.

Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.

Klotz U.

Dig Liver Dis. 2005 Jun;37(6):381-8. Epub 2005 Mar 2. Review.

PMID:
15893274
14.
15.

Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.

Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, Hentschel E, Kratochvil P.

Eur J Gastroenterol Hepatol. 1995 May;7(5):391-6.

PMID:
7614099
16.

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis.

Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D.

Aliment Pharmacol Ther. 2002 Feb;16(2):207-15.

17.

Aminosalicylates for induction of remission or response in Crohn's disease.

Lim WC, Wang Y, MacDonald JK, Hanauer S.

Cochrane Database Syst Rev. 2016 Jul 3;7:CD008870. doi: 10.1002/14651858.CD008870.pub2. Review.

PMID:
27372735
18.

Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

Ferry GD, Kirschner BS, Grand RJ, Issenman RM, Griffiths AM, Vanderhoof JA, Fiedorek SC, Winter HS, Hassall EG, Watkins JB, et al.

J Pediatr Gastroenterol Nutr. 1993 Jul;17(1):32-8.

PMID:
8102399
19.

A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.

Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.

Am J Gastroenterol. 2002 Jun;97(6):1398-407.

PMID:
12094857
20.

Mesalamine-induced lung toxicity.

Bitton A, Peppercorn MA, Hanrahan JP, Upton MP.

Am J Gastroenterol. 1996 May;91(5):1039-40. Review.

PMID:
8633548

Supplemental Content

Support Center